[account_shop_links]
Biologic Drug Product CDMO Benchmarking (7th Ed.)
$4,900.00 – $9,900.00
Licensing Options
- SINGLE-USER LICENSE
A Single-User License allows access to an individual user.
- ENTERPRISE-WIDE LICENSE
An Enterprise-Wide License allows access to all employees and sites within an organization.
Report Overview
Industry Standard Research (ISR) takes pride in our suite of Quality Benchmarking work and this study is no exception. The Biologic Drug Product CDMO Benchmarking (7th edition) has a wealth of information, created with two goals in mind: (1) Help biopharmaceutical companies make more informed CDMO selection decisions, and (2) Help CDMOs optimize operational and marketing strategies.
This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of outsourcing trends and practices. Included with this is a quantitative analysis of CDMO service quality across 24 performance attributes specific to outsourced drug product manufacturing. Discover the key attributes that contract manufacturing decision-makers are using to drive CDMO selection for biologic drug product manufacturing. Learn how individual CDMOs perform along important dimensions through analysis of 518 captured service encounters among 133 respondents.
What you will learn:
Drug Developers:
- Understand which manufacturers best fit your company’s needs and how individual CDMOs have performed compared to competition
- Discover which attributes have gained importance over the past 12 months among industry peers
- Compare how CDMOs are measuring up to sponsor-peer expectations across more than 20 attributes and hear directly from sponsors how their experience was with each CDMO, along with an overall satisfaction rating
Contract Manufacturers:
- Gain knowledge of your strengths and weaknesses and use this information to develop targeted messaging to showcase your perceived and real strengths
- Understand your performance – and compare among competitors – across 24 performance metrics specific to outsourced manufacturing
- Develop insight into drug developers’ outsourcing practices, preferences, and loyalty when it comes to CDMO selection for outsourcing biologic drug product manufacturing
Major Topics:
- Outsourcing Philosophies and Practices
- CDMO Selection Drivers
- CDMO Perceptions and Interactions
- CDMO Performance and Loyalty
- The Biologic Drug Product CDMO Competitive Landscape
- Company Service Quality Profiles
- Appendix
